Tests for beta amyloid protein (which causes the brain plaque associated with Alzheimer’s) and tau protein (causing brain neuron tangles in Alzheimer’s) are laboratory blood tests that require an order from your physician. These tests are designed to help diagnose Alzheimer’s and not provide genetic risk. GenoRisk Alzheimer’s is an at-home saliva test that looks at various single nucleotide polymorphims (SNPs) to establish a genetic risk for late-onset Alzheimer’s disease. The test is not intended to diagnose Alzheimer’s disease.

ADx Health’s GenoRisk Alzheimer’s test analyzes multiple genes rather than the APOE gene alone as in most other tests. Additionally, your GenoRisk Alzheimer’s Score is a “polygenic risk score” developed by cross-validating a number of statistical models that look at risk across various genes at one time instead of combining risk estimates for single genes. This means your results have a greater predictive accuracy than other tests.

GenoRisk Alzheimer’s is not indicated for individuals who have already been diagnosed with Alzheimer’s, although there may be benefit in having immediate family members take the GenoRisk Alzheimer’s test.

Anyone over the age of 18 who is interested in learning more about determining their genetic risk for late-onset Alzheimer’s Disease.

Anyone over the age of 18 who is interested learning their genetic risk for the most common type of Alzheimer’s Disease.

Setting up an ADx Health account allows you to register your kit(s) and have access to the Customer Portal to view your results and get important updates about your test(s).

Click on the “Register Your Kit” link in the upper right corner of the ADx website homepage at www.adxhealth.com. At the bottom of the Log In screen you’ll see “Don’t have an account, click here to sign up”. OR you can go directly to https://happ3pp.mindcreek.us/#/signupSingle.

Yes, this is the way we ensure that every individual completes a test questionnaire for their sample and gets their specific results.

Please contact Customer Support.

Happens to all of us! Please use the “Forgot password” button on the log in screen to receive an email with a link to reset your password. If we recognize your email, you’ll see a “Recovery email successfully sent” message in the “Reset password” screen. If you’re still having difficulty, please contact Customer Support.

We can’t provide you with results without being able to associate your unique barcoded sample with your personal information and your test questionnaire. If you forget to register your kit, we’ll send you a quick reminder email!

Click on the “Register Your Kit” link in the upper right corner of the ADx website homepage at www.adxhealth.com. OR scan the QR code located on the outside of your kit.

Your unique barcode is located in 3 different places: 1) On the outside of your kit. 2) On the sample collection tube in your kit. 3). On your “Contact Card” in the kit. Your barcode begins with “ADX” and is followed by 12 digits. For example: ADX-111-222-333-444. You’ll also be asked to provide your Sample Collection Date with a REMINDER you should print your initials and birthdate on the collection tube.

We all get distracted and busy! We’ll reach out to you on email to ask you to complete your registration.

Yes! You’ll receive an email from us letting you know your kit(s) have been successfully registered.

At this time ADx Health can only accept orders from U.S. residents and cannot ship internationally. Additionally, ADx Health cannot accept orders or samples from residents of New York state.

Yes, we’re happy to ship to a P.O. box.

Yes! You’ll receive an email letting you know that your kit is on the way with a tracking number!

You can either request a new shipping label through Customer Support or you can ship via USPS to: Avero Diagnostics, 3560 Meridian Street #101, Bellingham, WA 98225

Yes! We’ll email you when your sample has arrived and when testing has begun.

Kits don’t expire but we recommend you submit your sample as sooon as possible to accelerate your health and wellness journey!

Please contact Customer Support for a new kit.

Please contact Customer Support and we’ll send you a new kit.

Please contact Customer Support and we’ll send you a new kit.

Look at your barcoded tube and find either the 2.0 ml mark on the barcode label or the tube itself and fill to the mark not including any bubbles.

We’ll still try to use the sample you provided for testing, but we will send an email letting you know if we had to cancel your test. If we do cancel your test for insufficient sample reasons, we’ll send you another kit at no charge to you.

That’s when we’ll use your Contact Card to verify your identity and ensure we’re delivering results to the right person.

The information you share in your questionnaire helps us assess your overall health and factors that could influence your results and our recommendations.

Your results should be available within 10-15 days of receipt in our laboratory. A delay in your results may be due to issues with shipping services like inclement weather or other disruptions in service.

Along with an email notice of cancellation, you should have received additional instructions to contact Customer Support, as you may have not provided a sufficient volume of sample or your sample couldn’t be tested for other technical reasons. Customer Support will be happy to send you a new kit for testing at no charge.

Yes! You’ll receive an email letting you know that your results are in the Customer Portal.

Your results will be available through your account in the ADx Health Customer Portal. You’ll also be able to schedule a free 15 minute telehealth consult through your account in the Portal as well.

You can download and print your results from the Customer Portal.

Researchers study the genetics of Alzheimer’s disease through various approaches. One common method is to conduct genome-wide association studies (GWAS), where researchers analyze the DNA of large groups of individuals with and without Alzheimer’s disease to identify genetic variations associated with the condition. GWAS can help identify common genetic markers or variants that contribute to Alzheimer’s risk.

In addition to GWAS, researchers also investigate familial forms of Alzheimer’s disease caused by specific gene mutations. By studying families with a history of familial Alzheimer’s, researchers can identify the specific genes and mutations responsible for the disease. This type of research has led to the discovery of genes such as PSEN1, PSEN2, and APP, which play crucial roles in familial cases of Alzheimer’s.

Furthermore, researchers explore the functional impact of Alzheimer’s-related genes using cell culture models, animal models, and induced pluripotent stem cells (iPSCs) derived from patients’ skin cells. These models help elucidate the mechanisms by which genetic variants or mutations contribute to disease development and progression.

Overall, a combination of genetic studies, functional analyses, and ongoing research efforts contribute to our understanding of the genetics underlying Alzheimer’s disease.

Yes, there are ongoing efforts to develop personalized treatments for Alzheimer’s disease based on an individual’s genetic profile. Personalized or precision medicine approaches aim to target specific genetic factors, pathways, or mechanisms associated with Alzheimer’s disease in a tailored and individualized manner.

By understanding an individual’s genetic profile, including genetic risk factors and potential disease-causing mutations, researchers and clinicians can explore targeted interventions. This may involve developing drugs or therapies that specifically address the underlying mechanisms influenced by the individual’s genetic variants.

Ongoing research is investigating various strategies, including gene therapies, gene editing technologies, and drugs that target specific genetic risk factors or pathways implicated in Alzheimer’s disease. These efforts aim to develop treatments that are more effective, safer, and potentially more beneficial for individuals with specific genetic profiles.

Yes, genetic testing can be beneficial for individuals concerned about their Alzheimer’s risk, particularly those with a family history of the disease or individuals seeking more information about their genetic predisposition. Here are some potential benefits of genetic testing:

1. Risk awareness: Genetic testing can provide individuals with information about their genetic risk for Alzheimer’s disease. This knowledge can help them better understand their likelihood of developing the disease and make informed decisions about their health and future planning.
2. Early detection and prevention: Genetic testing may identify individuals who are at higher risk of developing Alzheimer’s in the future. With this information, individuals can take proactive steps to manage their risk factors, adopt healthy lifestyle choices, and engage in preventive measures to potentially delay or reduce the onset of the disease.
3. Personalized medical care: Genetic testing results can guide personalized medical care and disease management. Individuals who have a higher genetic risk can work with healthcare professionals to develop personalized screening plans, explore potential participation in research studies or clinical trials, and make informed decisions about treatment options if they become available in the future.
4. Emotional and psychological support: Genetic testing can provide individuals with a sense of closure or relief by either confirming a lower risk than expected or validating concerns about increased risk. It can also facilitate access to genetic counseling services, where individuals can discuss their concerns, receive emotional support, and gain a better understanding of the implications of their test results.

It is important to note that genetic testing for Alzheimer’s disease is a personal decision, and individuals should carefully consider the potential benefits, limitations, and implications before undergoing testing. Genetic counseling and/or consulting with a trained health professional is highly recommended to help individuals understand the test results and provide appropriate guidance and support.

Differentiating between genetic risk factors and causative genes for Alzheimer’s disease is a complex task that involves a combination of approaches, including genetic studies, functional analyses, and clinical observations.

Genetic risk factors are identified through genome-wide association studies (GWAS) or other genetic analyses that compare the genetic profiles of individuals with and without Alzheimer’s disease. These studies help identify common genetic variants associated with increased or decreased risk. However, the presence of a genetic risk factor does not necessarily indicate a direct causal role. Risk factors may be markers of increased susceptibility but not the sole cause of disease.

Causative genes, on the other hand, are identified through various methods, including studying families with inherited forms of the disease and identifying specific mutations in genes associated with disease development. Genetic variants or mutations in these genes are more likely to have a direct impact on disease causation. Functional analyses in cellular and animal models can further elucidate the mechanisms by which these genes contribute to Alzheimer’s pathogenesis.

Differentiating between genetic risk factors and causative genes requires careful study design, replication in independent cohorts, assessment of functional effects, and consideration of other factors that contribute to disease development. It is an ongoing process as researchers continue to uncover and validate genetic factors associated with Alzheimer’s disease.

Yes, genetic factors can influence the progression or severity of Alzheimer’s disease. The presence of certain genetic variants or mutations can affect disease onset, rate of cognitive decline, and overall disease progression.

For example, individuals with the APOE4 variant of the APOE gene generally experience an earlier onset of Alzheimer’s and may have a faster rate of cognitive decline compared to those without the variant. The number of APOE4 copies inherited (one or two) can also impact disease severity, with two copies often associated with a more aggressive form of the disease.

In familial Alzheimer’s cases caused by mutations in genes like PSEN1, PSEN2, or APP, the specific mutation can influence disease progression. Different mutations may lead to variations in the age of onset, the accumulation of specific protein fragments (e.g., amyloid-beta or tau), and the overall course of the disease.

It is important to note that while genetic factors can influence disease progression, other factors such as overall health, lifestyle, comorbidities, and environmental influences also contribute to the heterogeneity of Alzheimer’s disease progression.

Gene therapies and genetic interventions are actively being explored as potential treatments for Alzheimer’s disease. These approaches aim to modify or correct genetic factors that contribute to the disease. While there is no approved gene therapy for Alzheimer’s yet, several strategies are being investigated in preclinical and early clinical trials.

One approach involves using gene editing technologies, such as CRISPR-Cas9, to directly modify disease-associated genes or mutations in specific cells. This approach has shown promise in animal models, but there are still challenges to overcome before it can be safely and effectively applied in humans.

Another approach is gene delivery, where therapeutic genes are introduced into the brain to enhance cellular function, promote neuroprotection, or target the accumulation of toxic proteins like amyloid-beta. These therapies may involve viral vectors or other delivery systems to transport the therapeutic genes into targeted cells.

While gene therapies and genetic interventions hold potential, their development and translation into clinical applications require further research, including rigorous safety and efficacy testing. It is an area of active investigation, and ongoing studies are essential to assess the feasibility and long-term benefits of these approaches.

Yes, changes in gene expression and epigenetics can contribute to the development of Alzheimer’s disease. Epigenetics refers to modifications in gene expression that do not involve changes to the underlying DNA sequence. These modifications can include DNA methylation, histone modifications, and non-coding RNA molecules, which can affect how genes are activated or silenced.

Studies have shown alterations in epigenetic patterns in the brains of individuals with Alzheimer’s disease. These changes can influence the expression of genes involved in various processes, including amyloid-beta production, tau protein pathology, inflammation, and synaptic function. Epigenetic modifications may be influenced by a combination of genetic and environmental factors.

Understanding the role of epigenetics in Alzheimer’s disease is an active area of research. It offers insights into the complex interplay between genetics and the environment and may provide potential targets for therapeutic interventions in the future.

Yes, there is a difference in Alzheimer’s risk between familial and common Alzheimer’s cases. Familial Alzheimer’s disease (FAD) refers to cases where there is a clear inheritance pattern within families, typically caused by mutations in specific genes such as PSEN1, PSEN2, or APP. FAD accounts for a small proportion of Alzheimer’s cases (less than 5%).

In contrast, sporadic or common Alzheimer’s disease occurs in individuals without a clear family history and is the most common form of the disease. Common Alzheimer’s cases have a more complex etiology, involving a combination of genetic, environmental, and lifestyle factors. The APOE gene, particularly the APOE4 variant, is the most prominent genetic risk factor for common Alzheimer’s disease. However, having the APOE4 variant does not guarantee the development of the disease, and many individuals with common Alzheimer’s do not have a known genetic mutation.

The distinction between familial and common Alzheimer’s helps researchers understand different underlying mechanisms and has implications for genetic testing, counseling, and potential treatment approaches.

Age is the strongest risk factor for Alzheimer’s disease. The incidence of the disease increases with advancing age, and most cases occur in individuals over the age of 65. Age also interacts with genetic factors in influencing the risk of Alzheimer’s disease.

In common Alzheimer’s (also known as sporadic or late-onset Alzheimer’s), the APOE4 gene is the most well-known genetic risk factor. The influence of APOE4 on Alzheimer’s risk varies with age. The presence of APOE4 at a younger age (e.g., 40s or 50s) is associated with a higher relative risk of developing Alzheimer’s compared to individuals without the APOE4 variant. However, as individuals age, the contribution of APOE4 to the overall risk becomes less pronounced because age itself becomes the predominant risk factor. Other genetic risk factors, such as rare mutations in genes like PSEN1, PSEN2, and APP, are associated with familial Alzheimer’s and can have a more substantial impact on disease risk at younger ages. Nonetheless, it is important to remember that age remains the primary driver of Alzheimer’s risk, and genetic factors modulate that risk within the context of aging.

Understanding the genetics of Alzheimer’s disease is a complex and evolving field of research, and several challenges exist:

1. Genetic heterogeneity: Alzheimer’s disease is a complex disorder with a multifactorial etiology, involving the interplay of multiple genes, genetic variations, and environmental factors. The genetic heterogeneity of the disease makes it challenging to identify and understand the specific genetic contributions.
2. Gene-environment interactions: Genetic factors do not act in isolation but interact with environmental factors to influence disease risk. Unraveling these complex interactions and understanding how genes and the environment interact to influence Alzheimer’s risk is a significant challenge.
3. Variants with small effect sizes: Most genetic risk factors identified for Alzheimer’s disease have small effect sizes, meaning they individually contribute only a small increase in risk. Detecting and understanding the cumulative effect of multiple genetic variants with small effect sizes is challenging.
4. Non-genetic factors: Alzheimer’s disease is influenced by a range of non-genetic factors, such as lifestyle, environmental exposures, and comorbidities. Incorporating these factors into genetic studies and disentangling their interactions with genetic factors poses a challenge.
5. Limited therapeutic impact: Despite advances in genetic research, translating genetic findings into effective treatments or interventions for Alzheimer’s disease remains a challenge. Developing targeted therapies based on genetic factors is a complex process that requires a deep understanding of disease mechanisms.

Addressing these challenges requires interdisciplinary collaborations, larger sample sizes, integration of multiomics data (genomics, epigenomics, transcriptomics), and ongoing efforts to collect longitudinal data on both genetic and non-genetic factors associated with Alzheimer’s disease.

Yes, are numerous ongoing research studies and clinical trials focused on Alzheimer’s genes. These studies aim to deepen our understanding of the genetic factors associated with the disease and identify potential therapeutic targets. Some ongoing research areas include:

1. Identification of novel genetic risk factors: Researchers continue to explore the genome to uncover additional genetic variations that may contribute to Alzheimer’s disease risk. This involves large-scale genomic studies and collaborations across research institutions.
2. Functional characterization of genetic variants: Understanding how specific genetic variants or mutations affect cellular processes and brain function is crucial for unraveling the underlying mechanisms of Alzheimer’s disease. Researchers investigate the functional impact of genetic variants using various cellular and animal models.
3. Gene therapies and genetic interventions: Scientists are exploring the potential of gene therapies and genetic interventions to target and modify Alzheimer’s-related genes. This includes approaches such as gene editing technologies (e.g., CRISPR) to correct disease-causing mutations and gene delivery systems to introduce therapeutic genes.
4. Precision medicine and personalized treatments: The goal is to develop personalized treatments that take an individual’s genetic profile into account. Researchers aim to identify genetic markers that can predict treatment response and design interventions tailored to a person’s specific genetic risk factors.

These ongoing research efforts and clinical trials provide hope for better understanding Alzheimer’s genes and developing effective treatments for the disease.

www.alz.org is an excellent resource for learning more about Alzheimer’s Disease.

Genetic testing can provide information about an individual’s genetic risk factors for developing Alzheimer’s disease, but it does not currently play a significant role in early detection or prediction of the disease. The primary genetic test for Alzheimer’s disease involves analyzing the APOE gene variants (APOE2, APOE3, and APOE4), which can indicate an increased or decreased risk of developing the disease. However, it is important to note that having the APOE4 variant does not mean a person will definitely develop Alzheimer’s, and not having it does not guarantee protection.

It may provide some insights into a person’s genetic risk profile, but it cannot definitively predict whether or when an individual will develop the disease. Other diagnostic tools, such as cognitive assessments, biomarker tests, and neuroimaging, are currently used detecting and diagnosing Alzheimer’s disease.

While there is no guaranteed way to prevent Alzheimer’s disease, individuals can adopt preventive measures that may help reduce their risk or delay the onset of the disease. These measures include:

1. Engaging in regular physical exercise: Exercise has been linked to a lower risk of Alzheimer’s disease. It can improve cardiovascular health, promote blood flow to the brain, and support brain health.
2. Following a healthy diet and not smoking: A balanced diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats (such as the MIND, Mediterranean or DASH diets) may be beneficial. It is also recommended to limit processed foods, alcohol, saturated fats, and sugar.
3. Maintaining cardiovascular health: Conditions such as hypertension, diabetes, obesity, and high cholesterol can increase the risk of Alzheimer’s disease. Managing these conditions through lifestyle modifications and appropriate medical care may help reduce the risk.
4. Staying mentally and socially active: Engaging in mentally stimulating activities, such as puzzles, reading, learning new skills, and socializing, has been associated with better cognitive function and a lower risk of Alzheimer’s.
5. Getting quality sleep: Poor sleep or sleep disorders have been linked to an increased risk of cognitive decline. Prioritizing healthy sleep habits and addressing any sleep issues is important for overall brain health.
6. Managing stress: Chronic stress can have negative effects on brain health. Engaging in stress-reducing activities such as meditation, mindfulness, relaxation techniques, or hobbies can be beneficial.

It is essential to remember that these preventive measures are not guaranteed to prevent Alzheimer’s disease, but they may contribute to overall brain health and potentially reduce the risk or delay the onset of the disease.

The development of Alzheimer’s disease involves complex interactions between genetic and environmental factors. Genetic factors can influence an individual’s susceptibility to the disease, but they do not act in isolation. Environmental factors, such as lifestyle choices, education, occupation, cardiovascular health, and exposure to toxins, also play important roles in determining an individual’s risk.

Gene-environment interactions occur when genetic factors modify the effects of environmental exposures, or when environmental factors influence the expression of genes. For example, individuals with certain genetic variations may be more vulnerable to the detrimental effects of environmental factors like chronic stress, poor diet, or lack of physical activity. On the other hand, engaging in a healthy lifestyle may counteract or mitigate the genetic risk, demonstrating that lifestyle choices can modulate the impact of genetic factors.

Research suggests that adopting a healthy lifestyle can potentially offset the increased risk associated with genetic predispositions. By maintaining brain health, reducing inflammation, and promoting neuronal resilience, individuals may be able to modify their Alzheimer’s risk, even in the presence of genetic susceptibility.

Understanding the interplay between genetics and environmental factors is vital for developing personalized strategies for Alzheimer’s prevention and intervention. Further research is needed to unravel the complexities of these interactions and identify specific gene-environment interactions that influence Alzheimer’s risk.

Yes, lifestyle factors can play a significant role in modifying the impact of Alzheimer’s-related genes. While genes contribute to the risk, lifestyle choices can influence whether or not those genes are expressed or their effects are amplified. Engaging in a healthy lifestyle can potentially mitigate the risk or delay the onset of Alzheimer’s disease, even in individuals with genetic predispositions. Regular physical exercise, maintaining a balanced diet, managing cardiovascular health, maintaining cognitive and social engagement, and getting quality sleep have been associated with a reduced risk of developing Alzheimer’s. These lifestyle factors can promote brain health, reduce inflammation, improve blood flow, enhance cognitive reserve, and protect against age-related cognitive decline. It is important to adopt a holistic approach to Alzheimer’s prevention, considering both genetic and lifestyle factors in combination, to maximize the potential for maintaining brain health and reducing the risk of the disease.

Genetic testing can provide valuable information about an individual’s risk of developing Alzheimer’s disease, but it does not provide a definitive prediction or guarantee that the disease will occur. The primary genetic test for Alzheimer’s involves analyzing the APOE gene variants (APOE2, APOE3, and APOE4). Testing positive for the APOE4 variant can indicate an increased risk of developing Alzheimer’s, while having APOE2 may be associated with a reduced risk. However, it’s important to note that APOE4 is not the sole determinant of Alzheimer’s risk, and many individuals with APOE4 never develop the disease, while others without the variant do. Other genetic risk factors and various environmental influences contribute to the complex nature of Alzheimer’s disease. Therefore, while genetic testing can provide insights into an individual’s genetic risk profile, it should be interpreted alongside other factors, and genetic counselors or healthcare professionals can help provide a more comprehensive understanding of the results and their implications.

The heritability of Alzheimer’s disease refers to the proportion of the disease risk that can be attributed to genetic factors. Estimating the heritability of complex diseases like Alzheimer’s is challenging because multiple genetic and environmental factors are involved. Studies suggest that genetic factors contribute to about 60-80% of the overall risk of developing late-onset Alzheimer’s disease (the most common form of the disease). The APOE gene is the primary genetic risk factor, accounting for a significant portion of the heritability. However, it’s important to note that heritability does not mean that Alzheimer’s disease is solely determined by genes. Environmental factors, lifestyle choices, and complex gene-environment interactions also play significant roles in the development of the disease. Understanding the interplay between genetic and environmental factors is crucial for a comprehensive understanding of Alzheimer’s disease risk.

Yes, besides the APOE gene, several other genes have been identified as potential risk factors for Alzheimer’s disease, particularly in familial cases where the condition runs in families. These genes include presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP). Mutations in these genes can lead to the production or processing of amyloid-beta protein, which contributes to the formation of plaques in the brain. Variants in genes such as clusterin (CLU), phosphatidylinositol-binding clathrin assembly protein (PICALM), complement receptor 1 (CR1), and triggering receptor expressed on myeloid cells 2 (TREM2) have also been associated with an increased risk of Alzheimer’s disease, albeit with smaller effect sizes compared to APOE. These genes are involved in various processes related to brain inflammation, lipid metabolism, and synaptic function. However, it’s important to note that the presence of these genetic variants does not guarantee the development of Alzheimer’s, and the interplay between genetics, lifestyle, and environmental factors is complex.

The APOE gene provides instructions for producing a protein called apolipoprotein E, which plays a role in transporting and metabolizing fats in the body, including in the brain. The APOE gene has three common variants: APOE2, APOE3, and APOE4. APOE4 is the variant most strongly associated with an increased risk of developing Alzheimer’s disease. Inheriting one copy of APOE4 from either parent increases the risk, while inheriting two copies further elevates the risk. The exact mechanisms by which APOE4 increases Alzheimer’s risk are not fully understood, but it is thought to affect the clearance and accumulation of amyloid-beta plaques in the brain, a hallmark characteristic of Alzheimer’s. APOE4 is also believed to impact neuroinflammation, tau protein abnormalities, and synaptic function, contributing to the disease’s pathogenesis. However, it is important to note that possessing the APOE4 variant does not mean a person will definitely develop Alzheimer’s, and other factors, such as lifestyle and environmental influences, also contribute to the overall risk.

Genetic factors play a role in the development of Alzheimer’s disease by influencing an individual’s susceptibility to the condition. Certain genes can increase the risk or alter the age of onset for Alzheimer’s. For example, the APOE4 variant of the APOE gene is associated with an increased risk and earlier onset of the disease. The presence of APOE4 may influence the metabolism and accumulation of amyloid-beta, a protein that forms plaques in the brains of individuals with Alzheimer’s. Additionally, genes such as PSEN1, PSEN2, and APP are involved in the processing and production of amyloid-beta. Mutations in these genes can lead to an overproduction or altered processing of amyloid-beta, contributing to the development of the disease. While genetic factors are important, it’s worth noting that they are just one piece of the puzzle, and environmental and lifestyle factors also play significant roles in the development of Alzheimer’s disease.

Yes, several genetic markers and genes have been associated with an increased risk of developing Alzheimer’s disease. The most well-known and studied genetic risk factor is the apolipoprotein E (APOE) gene. There are three common variants of the APOE gene: APOE2, APOE3, and APOE4. APOE4 is known to increase the risk of developing Alzheimer’s disease, while APOE2 seems to have a protective effect. However, it’s important to note that possessing the APOE4 variant does not guarantee the development of Alzheimer’s, and not having APOE4 does not completely rule out the possibility. Other genes, such as the presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) genes, have also been implicated in familial cases of Alzheimer’s disease, where the condition runs in families.

We discard your sample 2 weeks after we’ve completed the test(s) you’ve asked us to perform. The sample is maintained for 2 weeks should there be an issue requiring us to rerun your test(s).

We’ll store your sample for a period of one year to collect data and/or run additional tests for research, clinical trial elegibility, quality improvements and test enhancements unless you chose to not to allow us to do so. If you DO NOT wish to have your sample stored, you can email our Privacy Officer at privacy@adxhealth.com for exclusion and your sample will be destroyed after 2 weeks as per retention compliance with applicable legal obligations, including the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA), California Business and Professions Code Section 1265 and College of American Pathologists (CAP) accreditation requirements. Your genetic Information, date of birth, and sex will also be stored.

Can we flesh this out a little?

ADx Health may share or sell your de-identified data to the likes of pharmaceutical and biotechnology companies, academic institutions or nonprofit organizations. ADx Health will NOT voluntarily share or sell your data with public databases, insurance companies or employers, or law enforcement or regulatory authorities. If you DO NOT wish to participate in data sharing or research, you can email our Privacy Officer at privacy@adxhealth.com for exclusion.

You can contact privacy@adxhealth.com and request to no longer participate in data sharing or research.

Yes, ADx Health will delete your data after retention compliance with applicable legal obligations, including the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA), California Business and Professions Code Section 1265 and College of American Pathologists (CAP) accreditation requirements.

Yes, your account can be deleted by contacting Customer Support.

We make every effort to provide the highest level of security and protection for your data and personal health information (PHI). We have instituted physical, technical and administrative procedures to prevent unauthorized access to or disclosure of your personal information. We restrict who can have access to your data and regularly review our procedures to ensure the integrity of our systems and practices.

Please go to https://adxhealth.com/privacy-statement/

Yes, the ADx Health website will provide notification of a policy change at www.adxhealth.com

HIPAA Notice of Privacy Practices

Email: privacy@adxhealth.com. Phone: 360-527-4580. Mail: ADx Health Privacy Officer, 3560 Meridian Street, Suite 101, Bellingham, WA 98225